Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
These 3 Nail-Free Finds Completely Transformed My Drab Bathroom - 2Holiday weather forecast: Where travelers can expect a wintry mix, flooding and record warmth across the U.S.
- 36 Agreeable Earphones To Wear
- 4Overlooked infertility care should be part of national health services, says WHO
- 5Dominating Online Entertainment Showcasing: 7 Hints for Organizations
- The Extraordinary Excursion of Dental Embed Innovation
- Nations for Youngsters to Visit
- Slims down for Maintainable Weight reduction
- Instructions to Improve Your Mental Exploration with Cutting edge Measurements
- Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment
- A quick recap of 'Stranger Things' Seasons 1-4, plus key episodes to rewatch before Volume 1 of the final season drops
- Grasping Wrongdoings and Crimes: A Correlation
- 23 Most Amusing Messages At any point Sent Among Youngsters and Their Folks
- Early diagnosis leads King Charles to scale back cancer treatment in the new year
